Diablo Clinical Research   Report issue

For profit Phase 2 Phase 3
Founded: Walnut Creek CA United States (1995)

Organization Overview

First Clinical Trial
2007
NCT00409305
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Diablo Clinical Research | Diablo Clinical Research, Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

bifidobacterium bifidum (1 trial)

gynatren (1 trial)

lactobacillus delbrueckii (1 trial)

Drugs in Phase 2 Trials (2)

betahistine (1 trial)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Body Weight (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Gastrointestinal Diseases (Phase 3)

Signs and Symptoms, Digestive (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5